- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07251478
Transparent Communication to Improve Mental Wellbeing and Attitude Towards Reintegration
November 24, 2025 updated by: Tarela Ike, Teesside University
Transparent Communication to Improve Mental Wellbeing and Public Attitude Towards the Reintegration of Former Boko Haram Members in Nigeria: A Pilot Randomised Control Trial
Reintegrating those once affiliated with proscribed terrorist groups constitutes significant global challenges due to public stigma, poor awareness of reintegration programmes and resentment towards incentives provided to rehabilitated former members of such groups.
Of central concern is the anxiety, trauma and depression suffered alongside distrust for reintegration programmes, including the genuine repentance of former members of the proscribed group.
The implication is its risk in exacerbating reoffending.
Yet, a gap exists to address this urgent problem.
The proposed study seeks to test and pilot the feasibility and acceptability of a novel intervention called Prosociality, Empathy and Awareness Communication to aid rEintegration (PEACE) in improving mental well-being and public attitude towards reintegration.
The intervention is a low-intensity intervention lasting approximately 3-5 minutes design to create awareness on the rationale behind reintegration programme, reduce anxiety, depression and foster positive attitude towards reintegration.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
74
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tarela J Ike, PhD
- Phone Number: 0164234231
- Email: T.ike@tees.ac.uk
Study Contact Backup
- Name: Dung E Jidong, PhD
- Email: Dung.jidong@manchester.ac.uk
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 18 years and above
- Able to provide full consent for their participation.
- A resident of the study areas
Exclusion Criteria:
- Less than 18 years
- Unable to consent
- Currently undergoing severe mental health treatment
- Unable to speak the English language fluently
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Prosociality, Empathy and Awareness Communication to aid rEintegration (PEACE)
The Prosociality, Empathy and Awareness Communication to aid rEintegration (PEACE) intervention is a low-intensity intervention lasting 3-5 minutes.
|
The Prosociality, Empathy and Awareness Communication to aid rEintegration (PEACE) intervention is a low-intensity intervention lasting 3-5 minutes.
The intervention is underpinned by awareness creation, reducing depression and anxiety and the purpose of reintegration programme to encourage change in negative attitudes towards reintegration.
The recorded message introduction will commence with a welcome address on the topic, and this is followed by the core message and a closing remark.
The core message is composed of three key ambits: 1) emphasizing mental health and welbeing alongside the importance of the reintegration programme, the rationale behind the reintegration programme, including the provision of incentives to dissuade reoffending, (ii) the need for empathy, prosociality, and positive social identity and advantages of reintegration and (iii) calling on the public to forgive and accept them back.
The programme will end with a thank you to the audience for listening.
|
|
No Intervention: Control - Waitlist Group
The control group will not receive an intervention until after the assessment periods at baseline (day 1), and end of intervention (day 2) before they will be administered the PEACE intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Service Satisfaction Scale
Time Frame: At the end of intervention (day 2)
|
A five item scale that can be used to assess and measure satisfaction, acceptability and quality of the intervention.
Higher score denote positive outcomes and acceptability.
Lower score denotes poor satisfaction and acceptability.
|
At the end of intervention (day 2)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-traumatic Stress Disorder Checklist (PCL-5)
Time Frame: Baseline (day 1) and at the end of intervention (day 2)
|
The PCL-5 is a 20-item self-report measure that can be used to assess the 20 DSM-5 symptoms of post traumatic stress disorder.
A 5-10 point change represents reliable change (i.e., change not due to chance) and a 10-20 point change represents clinically significant change.
|
Baseline (day 1) and at the end of intervention (day 2)
|
|
Generalised Anxiety Disorder (GAD-7)
Time Frame: Baseline (day 1) and at the end of intervention (day 2)
|
The GAD-7 is a seven item scale for screening, measuring and assessing the severity of generalised anxiety disorder.
Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively.
|
Baseline (day 1) and at the end of intervention (day 2)
|
|
Oslo Social Support Scale (OSSS-3)
Time Frame: Baseline (day 1) and at the end of intervention (day 2)
|
The scale is a 3-item self-reported measure designed for assessing and measuring the level of social support.
The sum score ranges from 3 to 14, with high values representing strong levels and low values representing poor levels of social support as indicated as follows: a) 3-8 poor social support, b) 9-11 moderate social support, c) 12-14 strong social support.
|
Baseline (day 1) and at the end of intervention (day 2)
|
|
Patient Health Questionnaire (PHQ-9)
Time Frame: Baseline (day 1) and at the end of intervention (day 2)
|
The Patient Health Questionnaire (PHQ-9) is a 9-item questionnaire that will be used for screening, monitoring, measuring and assessing the severity of depression.
Low scores (e.g.
0-4) indicate no depression, however, higher scores (20-27) indicates severe depression.
|
Baseline (day 1) and at the end of intervention (day 2)
|
|
European Quality of Life Scale EQ-5D-5L
Time Frame: Baseline (day 1) and at the end of intervention (day 2)
|
The EQ-5D-5L is a 5 item scale designed to aid assessment of the generic quality of life.
In the EQ-5D-5L, each dimension has five response levels: no problems (Level 1); slight (Level 2); moderate (Level 3); severe (Level 4); and extreme problems (Level 5).
There are 3,125 possible health states defined by combining one level from each dimension, ranging from 11111 (full health) to 55555 (worst health).
|
Baseline (day 1) and at the end of intervention (day 2)
|
|
Legal-informed Awareness of Complaint Channel Scale (LACCS)
Time Frame: Baseline (day 1) and at the end of intervention (day 2)
|
The LACCS is a 10-item scale that is designed for assessing and measuring level of awareness of complaint channels and legal rights.
The scale has an overall rating of 30, with 0-7 indicating poor knowledge, 8-15 (average knowledge), 16-22 (good knowledge) and 23-30 (excellent knowledge).
|
Baseline (day 1) and at the end of intervention (day 2)
|
|
Attitude Towards Repentant Terrorist and their Reintegration Scale (ATRTRS)
Time Frame: Baseline (day 1) and at the end of intervention (day 2)
|
The scale os a 26-item scale that is designed for assessing attitude towards repentant terrorist and their reintegration.
The scale has a total score of 130 and assigned the following rating: 1 = Extremely poor reintegration attitude (1-26); 2 = Poor reintegration attitude (27-52); 3 = Moderate attitude towards reintegration (53-78); 4 = Good attitude towards reintegration (79-104); and 5 = Very good attitude towards reintegration (105-130).
|
Baseline (day 1) and at the end of intervention (day 2)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vignette
Time Frame: Baseline (day 1) and at the end of intervention (day 2)
|
The vignette will be based on hypothetical ex-Boko Haram members, fighter and those forced to join with varying roles within the group and what they did as appropriate.
The participants will then be asked 3 sets of outcome measures which relates to Behavioural attitude, emotions and attitude towards reintegration programme.
|
Baseline (day 1) and at the end of intervention (day 2)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Owonikoko, S. B. (2022). "Take them to government house or Aso Rock": Community receptivity to reintegration of operation safe corridor's deradicalised Ex-Boko Haram members in Northeastern Nigeria. Cogent Social Sciences, 8(1), 2015884.
- Abdullahi, I., & Onabanjo, H. (2024). Reintegration of ex-combatants and peacebuilding in terrorised communities in northeastern Nigeria. International Journal of Research and Innovation in Social Science (IJRISS), 9 (7), 2283, 2307.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
December 10, 2025
Primary Completion (Estimated)
September 30, 2026
Study Completion (Estimated)
September 30, 2026
Study Registration Dates
First Submitted
May 20, 2025
First Submitted That Met QC Criteria
November 24, 2025
First Posted (Actual)
November 26, 2025
Study Record Updates
Last Update Posted (Actual)
November 26, 2025
Last Update Submitted That Met QC Criteria
November 24, 2025
Last Verified
November 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0000-0003-0516-0313g
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Data supporting this study cannot be made available due to the sensitive nature and ethical reasons on confidentiality.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of CincinnatiNational Center for Complementary and Integrative Health (NCCIH)RecruitingMild DepressionUnited States
-
University of MinnesotaCompletedDepression SymptomsUnited States
Clinical Trials on Prosociality, Empathy and Awareness Communication to aid rEintegration (PEACE)
-
Indiana UniversityMedical University of South Carolina; National Institute of Diabetes and Digestive... and other collaboratorsRecruiting